Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Accumulated Depreciation (2024 - 2025)

CG Oncology's Accumulated Depreciation history spans 2 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation rose 1594.25% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 1594.25%, while the annual FY2025 figure was $1.5 million, 1594.25% up from the prior year.
  • Accumulated Depreciation reached $1.5 million in Q4 2025 per CGON's latest filing, up from $623000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $1.5 million in Q4 2025 to a low of $87000.0 in Q4 2024.